Clinicopathological characteristics and outcome of DLBCLs treated with R-CHOP
| . | Overall . | DP . | Non-DP . | P value . | ||
|---|---|---|---|---|---|---|
| N (%) . | OS, P . | PFS, P . | N (%) . | N (%) . | ||
| Patients | 466 (100) | 157 (100) | 309 (100) | |||
| Gender | ||||||
| Male | 272 (58) | .7477 | .4730 | 90 (57) | 182 (59) | .7445 |
| Female | 194 (42) | 67 (43) | 127 (41) | |||
| Age | ||||||
| ≤60 | 194 (42) | .0004 | .0016 | 49 (31) | 145 (47) | .0011 |
| >60 | 272 (58) | 108 (69) | 164 (53) | |||
| B symptoms* | ||||||
| Absence | 276 (68) | .0015 | .0014 | 88 (62) | 188 (72) | .0541 |
| Presence | 127 (32) | 53 (38) | 74 (28) | |||
| ECOG performance status* | ||||||
| <2 | 350 (88) | <.0001 | <.0001 | 111 (83) | 239 (90) | .0453 |
| ≥2 | 50 (12) | 23 (17) | 27 (10) | |||
| Stage* | ||||||
| I-II | 219 (49) | <.0001 | <.000l | 50 (33) | 169 (57) | <.0001 |
| III-IV | 228 (51) | 100 (67) | 128 (43) | |||
| Extranodal sites* | ||||||
| <2 | 346 (78) | <.0001 | <.000l | 106 (72) | 240 (82) | .0160 |
| ≥2 | 96 (22) | 42 (28) | 54 (18) | |||
| Lactate dehydrogenase* | ||||||
| Normal | 168 (40) | .0003 | <.000l | 51 (36) | 117 (42) | .2908 |
| Elevated | 252 (60) | 89 (64) | 163 (58) | |||
| IPI risk group* | ||||||
| 0-2 | 263 (64) | <.000l | <.0001 | 70 (51) | 193 (70) | .0001 |
| 3-5 | 148 (36) | 67 (49) | 81 (30) | |||
| Tumor size, cm* | ||||||
| <7.5 | 253 (77) | .0100 | .0172 | 81 (73) | 172 (79) | .2587 |
| ≥7.5 | 77 (23) | 30 (27) | 47 (21) | |||
| Treatment response | ||||||
| CR | 354 (76) | <.000l | <.000l | 103 (66) | 251 (84) | <.0001 |
| Others | 112 (24) | 54 (34) | 48 (16) | |||
| COO classification | ||||||
| GCB | 241 (52) | .0080 | .0075 | 53 (34) | 188 (61) | <.0001 |
| ABC | 225 (48) | 104 (66) | 121 (39) | |||
| Ki-67* | ||||||
| <7O | 158 (34) | .2998 | .3434 | 41 (26) | 117 (38) | .0086 |
| ≥70 | 304 (66) | 116 (74) | 188 (62) | |||
| TP53 mutations | ||||||
| Absence | 357 (77) | 117 (75) | 240 (78) | .4480 | ||
| Presence | 109 (23) | .0005 | .0004 | 40 (25) | 69 (22) | |
| . | Overall . | DP . | Non-DP . | P value . | ||
|---|---|---|---|---|---|---|
| N (%) . | OS, P . | PFS, P . | N (%) . | N (%) . | ||
| Patients | 466 (100) | 157 (100) | 309 (100) | |||
| Gender | ||||||
| Male | 272 (58) | .7477 | .4730 | 90 (57) | 182 (59) | .7445 |
| Female | 194 (42) | 67 (43) | 127 (41) | |||
| Age | ||||||
| ≤60 | 194 (42) | .0004 | .0016 | 49 (31) | 145 (47) | .0011 |
| >60 | 272 (58) | 108 (69) | 164 (53) | |||
| B symptoms* | ||||||
| Absence | 276 (68) | .0015 | .0014 | 88 (62) | 188 (72) | .0541 |
| Presence | 127 (32) | 53 (38) | 74 (28) | |||
| ECOG performance status* | ||||||
| <2 | 350 (88) | <.0001 | <.0001 | 111 (83) | 239 (90) | .0453 |
| ≥2 | 50 (12) | 23 (17) | 27 (10) | |||
| Stage* | ||||||
| I-II | 219 (49) | <.0001 | <.000l | 50 (33) | 169 (57) | <.0001 |
| III-IV | 228 (51) | 100 (67) | 128 (43) | |||
| Extranodal sites* | ||||||
| <2 | 346 (78) | <.0001 | <.000l | 106 (72) | 240 (82) | .0160 |
| ≥2 | 96 (22) | 42 (28) | 54 (18) | |||
| Lactate dehydrogenase* | ||||||
| Normal | 168 (40) | .0003 | <.000l | 51 (36) | 117 (42) | .2908 |
| Elevated | 252 (60) | 89 (64) | 163 (58) | |||
| IPI risk group* | ||||||
| 0-2 | 263 (64) | <.000l | <.0001 | 70 (51) | 193 (70) | .0001 |
| 3-5 | 148 (36) | 67 (49) | 81 (30) | |||
| Tumor size, cm* | ||||||
| <7.5 | 253 (77) | .0100 | .0172 | 81 (73) | 172 (79) | .2587 |
| ≥7.5 | 77 (23) | 30 (27) | 47 (21) | |||
| Treatment response | ||||||
| CR | 354 (76) | <.000l | <.000l | 103 (66) | 251 (84) | <.0001 |
| Others | 112 (24) | 54 (34) | 48 (16) | |||
| COO classification | ||||||
| GCB | 241 (52) | .0080 | .0075 | 53 (34) | 188 (61) | <.0001 |
| ABC | 225 (48) | 104 (66) | 121 (39) | |||
| Ki-67* | ||||||
| <7O | 158 (34) | .2998 | .3434 | 41 (26) | 117 (38) | .0086 |
| ≥70 | 304 (66) | 116 (74) | 188 (62) | |||
| TP53 mutations | ||||||
| Absence | 357 (77) | 117 (75) | 240 (78) | .4480 | ||
| Presence | 109 (23) | .0005 | .0004 | 40 (25) | 69 (22) | |
DP, MYC/BCL2 double positive by IHC; ECOG, Eastern Cooperative Oncology Group; Non-DP, non-MYC/BCL2 double positive.
Information not available in some cases.